What additional filing is AIM (AIM) making related to this amendment?

AIM is filing a supplement to its existing prospectus supplement with the SEC. This new supplement increases the number of shares that may be offered and sold in the at-the-market offering under the amended Equity Distribution Agreement.

AIM ImmunoTech expands at-the-market stock program

AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering.

Accepted by SEC EDGAR 04/10/2026 - 04:33 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering. The original agreement covered issuance and sale of up to $3,000,000 of common shares.

The amendment removes the limitation on the amount of shares that may be sold under the agreement, allowing additional sales under the company’s effective shelf registration statement on Form S-3 and related prospectus. AIM is also filing a new prospectus supplement to increase the number of shares that may be offered and sold through this at-the-market program.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Previous ATM capacity: $3,000,000 of common stock

1 metrics

Previous ATM capacity $3,000,000 of common stock Maximum amount of shares under original Equity Distribution Agreement

Key Terms

Equity Distribution Agreement, at-the-market public offering, shelf registration statement on Form S-3, prospectus supplement, +1 more

5 terms

Equity Distribution Agreement financial

"entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025"

An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.

at-the-market public offering financial

"from time to time, in an at-the-market public offering (the “Offering”)"

A public offering in which a company sells newly issued shares directly into the open market at the prevailing market price over a period of time, using a broker-dealer to place orders on the exchange as conditions permit. Sales occur incrementally under a standing program (often called an ATM program) rather than in a single block, so the company raises cash when it chooses and receives the proceeds minus broker fees; the number, timing and price of shares sold depend on market liquidity and the program’s terms.

shelf registration statement on Form S-3 regulatory

"pursuant the Company’s shelf registration statement on Form S-3 (File No. 333-286319)"

A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.

prospectus supplement regulatory

"filing a supplement to the prospectus supplement with the Securities and Exchange Commission"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

emerging growth company regulatory

"Emerging growth company Securities registered pursuant to Section 12(b) of the Act"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did AIM (AIM) amend on April 10, 2026?

AIM ImmunoTech Inc. amended its Equity Distribution Agreement with Maxim Group LLC. This agreement appoints Maxim as exclusive sales agent for issuing and selling AIM common stock through an at-the-market offering program.

How much stock was AIM (AIM) originally able to sell under the Equity Distribution Agreement?

The original Equity Distribution Agreement covered issuance and sale of up to $3,000,000 of AIM common stock. This figure defined the previous maximum capacity of the company’s at-the-market stock offering program with Maxim Group LLC.

What change does the new amendment make to AIM’s (AIM) at-the-market program?

The amendment removes the prior limitation on the amount of shares that may be sold under the Equity Distribution Agreement. This allows AIM to sell additional common shares through its existing at-the-market offering structure with Maxim Group LLC.

Under what registration is AIM (AIM) selling shares in this at-the-market offering?

AIM is selling shares pursuant to its shelf registration statement on Form S-3, File No. 333-286319. This registration statement has been declared effective and is used together with a related base prospectus and supplements.

Who is acting as AIM’s (AIM) exclusive sales agent in the at-the-market offering?

Maxim Group LLC is acting as AIM ImmunoTech Inc.’s exclusive sales agent. Under the Equity Distribution Agreement, Maxim arranges the issuance and sale of AIM’s common stock in at-the-market transactions pursuant to the company’s shelf registration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 10, 2026

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

Delaware	001-27072	52-0845822
(state or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

2117 SW Highway 484, Ocala, FL		34473
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (352) 448-7797

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AIM		NYSE American

Item 1.01 Entry into a Material Definitive Agreement.

On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”). The Amendment removes the limitation of the amount of Shares to be sold under the Sales Agreement.

The Shares will be sold and issued pursuant the Company’s shelf registration statement on Form S-3 (File No. 333-286319), which was previously declared effective by the Securities and Exchange Commission, and a related prospectus, as supplemented. The Company is simultaneously herewith filing a supplement to the prospectus supplement with the Securities and Exchange Commission to increase the number of Shares that may be offered and sold in the Offering.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description

3.1		Amendment to Equity Distribution Agreement dated April 10, 2026

5.1		Opinion of Thompson Hine LLP

23.1		Consent of Thompson Hine LLP (included in the opinion filed as Exhibit 5.1)

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AIM ImmunoTech Inc.

Dated: April 10, 2026	/s/ Thomas K. Equels
	Thomas K. Equels, CEO

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

8 documents